Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/CSTONE-PHARMACEUTICALS-57946082/news/CStone-Pharmaceuticals-gibt-bekannt-dass-die-Zulassungsstudie-mit-Sugemalimab-zur-Erstlinienbehandl-44759115/?utm_source=whatsapp&utm_medium=social&utm_campaign=share